I think the next news should be the dosing of newly diagnosed AML patients withour NK cell drug in combination with SOC. This is important, as getting the drug used early in the treatment will quickly show any benefit. This should happen before the end of the year. There may also be another up to the phase 1a data in GBM, end of this year early next.
Next year, if all 4 trials get underway there will be plenty of announcements mid year to end of year. Potentially the progressing into a phase 2b accelerated approval trial for GBM.
Lots to be excited about here.
CHM Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)